Login to Your Account

Celgene launches $7B bid for Impact Biomedicines

By Michael Fitzhugh
Staff Writer

Monday, January 8, 2018

SAN FRANCISCO – The 36th Annual J.P. Morgan Healthcare Conference started off with a bang Monday, as Celgene Corp. talked up a proposed $7 billion acquisition of Impact Biomedicines Inc. built around Impact’s lead candidate, fedratinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription